Clinical Trial Update: Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the efficacy and safety of topical resiquimod gel 0.06% for nodular basal cell carcinoma was terminated, with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nodular Basal Cell Carcinoma

Drugs mentioned

• Resiquimod topical gel 0.06% (Resiquimod)

Snippet

Sponsor: Spirig Pharma Ltd. | Conditions: Nodular Basal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-06-22